2015 - Webinar On Managing the FDA form 483 Inspection Observations
Date2015-05-12
Deadline2015-05-12
VenueMississauga, Canada
KeywordsFDA form 483 Inspection; Form FDA 483; FDA regulations
Topics/Call fo Papers
Description :
This webinar is a complete guide on how to manage the FDA's 483 observations during and after an inspection. How you respond can make or break you.
Form FDA 483 is a list of observations made by FDA during an inspection. Observations are not a good thing. At the conclusion of an inspection, the FDA investigator lists specific examples that demonstrate an apparent violation of the applicable FDA regulations. You and the FDA investigator will discuss what the investigator found. At that point you are put on notice about your problems. You are warned that if you fail to correct the problems, it may result in further action by the FDA, such as levying civil money penalties, seizure, injunction, and/or prosecution. Firms are well advised to take the written 483 observations and FDA’s verbal warning seriously. A failure to promptly respond in writing to the FDA makes the situation even worse. As an immediate business consequence, marketing departments should expect competitors to show customers your 483. Your 483 is used against you as a bad report.
Prior to an inspection, the FDA investigator reviews your prior 483s and checks to make sure you corrected your previous problems. You will be held accountable for your prior response. What you promised to correct and what you did not correct becomes a critical factor in how FDA classifies your firm. What you fail to correct may lay for the foundation for long-term serious consequences with FDA. Your firm’s management is held accountable for its failure to adequately correct its regulatory problems. In some cases, the FDA will hold senior executive management personally liable for their managerial actions or inaction. Again, what a firm promises and what a firm does in response to a 483 makes a real difference.
Areas Covered in the Session :
What the Form FDA “483” means
How to manage the FDA’s 483 observations during and after an inspection
What the FDA considers important
How to respond effectively to 483 observations
Planning for other problems
Learn how to manage your regulatory profile with the FDA
Who Will Benefit:
Regulatory Affairs Professionals
In-house Legal Counsel
Senior Managers for Manufacturing and Quality Assurance
FDA consultants
Senior Operations and Finance Executives
Public Relations Professionals
Senior Executive Management
Marketing
Price tags:
Live
Single Live : For One Participant
$ 249
Corporate Live : For Max. 10 Participants
$ 899
Recording
Single REC : For One Participant - Unlimited Access for 6 Months
$ 299
For more information and enquiries contact us at
Compliance Trainings
5939 Candlebrook Ct, Mississauga, ON L5V 2V5, Canada
Customer Support : #416-915-4458
Email : support-AT-compliancetrainings.com
For more information about this event please visit
https://compliancetrainings.com/SiteEngine/Product...
Like Us On Facebook:
https://www.facebook.com/events/1619168248303672
This webinar is a complete guide on how to manage the FDA's 483 observations during and after an inspection. How you respond can make or break you.
Form FDA 483 is a list of observations made by FDA during an inspection. Observations are not a good thing. At the conclusion of an inspection, the FDA investigator lists specific examples that demonstrate an apparent violation of the applicable FDA regulations. You and the FDA investigator will discuss what the investigator found. At that point you are put on notice about your problems. You are warned that if you fail to correct the problems, it may result in further action by the FDA, such as levying civil money penalties, seizure, injunction, and/or prosecution. Firms are well advised to take the written 483 observations and FDA’s verbal warning seriously. A failure to promptly respond in writing to the FDA makes the situation even worse. As an immediate business consequence, marketing departments should expect competitors to show customers your 483. Your 483 is used against you as a bad report.
Prior to an inspection, the FDA investigator reviews your prior 483s and checks to make sure you corrected your previous problems. You will be held accountable for your prior response. What you promised to correct and what you did not correct becomes a critical factor in how FDA classifies your firm. What you fail to correct may lay for the foundation for long-term serious consequences with FDA. Your firm’s management is held accountable for its failure to adequately correct its regulatory problems. In some cases, the FDA will hold senior executive management personally liable for their managerial actions or inaction. Again, what a firm promises and what a firm does in response to a 483 makes a real difference.
Areas Covered in the Session :
What the Form FDA “483” means
How to manage the FDA’s 483 observations during and after an inspection
What the FDA considers important
How to respond effectively to 483 observations
Planning for other problems
Learn how to manage your regulatory profile with the FDA
Who Will Benefit:
Regulatory Affairs Professionals
In-house Legal Counsel
Senior Managers for Manufacturing and Quality Assurance
FDA consultants
Senior Operations and Finance Executives
Public Relations Professionals
Senior Executive Management
Marketing
Price tags:
Live
Single Live : For One Participant
$ 249
Corporate Live : For Max. 10 Participants
$ 899
Recording
Single REC : For One Participant - Unlimited Access for 6 Months
$ 299
For more information and enquiries contact us at
Compliance Trainings
5939 Candlebrook Ct, Mississauga, ON L5V 2V5, Canada
Customer Support : #416-915-4458
Email : support-AT-compliancetrainings.com
For more information about this event please visit
https://compliancetrainings.com/SiteEngine/Product...
Like Us On Facebook:
https://www.facebook.com/events/1619168248303672
Other CFPs
- Webinar On Effective Documentation of Employee Performance to Avoid Lawsuits
- Webinar On Method Validation: Utilizing Quality by Design (QbD) and Risk in Implementation
- Webinar On Developing a Compliance Risk Management (CRM) Model for Your Company
- Webinar On Handling Difficult Conversations with Employees
- Webinar On Current Good Manufacturing Practices (cGMP) for Medical Devices and IVDs
Last modified: 2015-04-14 18:29:53